Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors

Chen, Zhiwei; Zhu, Peng; Liu, Zuojin; Zhu, Bin; Yin, Guoyong; Ming, Jia; Song, Rui; Pan, Qingbo; Li, Tong; Jiang, Xingwei; Wang, Bing; Liu, Shuaibin; Cai, Hongxing; Wang, Jingjie; Han, Yuling; Lin, Zijing; Hong, Tang Hong, Yang Ming, Li; Chen, Min; Peng, Mingli; Hu, Lina; Cai, Dachuan; Ren, Hong

doi:10.1002/cac2.12368

Cited by 4 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti‐RBD‐IgG and NAbs in the serum samples were detected using capture chemiluminescence immunoassays with MAGLUMI X8 (Snibe), as described in our previous study 18 . The sensitivity and specificity of kits (Snibe) for anti‐RBD‐IgG were 100% and 99.6%, and those for NAbs were 100% and 100%, respectively.…”

Section: Participants and Methodsmentioning

confidence: 99%

“…SARS‐CoV‐2‐specific MBCs were detected by flow cytometry as described previously 18 . In brief, biotinylated SARS‐CoV‐2 Spike RBD protein (Sino Biological, 40592‐V08H2‐B) was mixed with Streptavidin BV421 (Biolegend, 405225) at a 4:1 molar ratio for 1 h at 4°C to obtain the antigen probe.…”

Section: Participants and Methodsmentioning

confidence: 99%

“…SARS-CoV-2-specific MBCs were detected by flow cytometry as described previously. 18 In brief, biotinylated SARS-CoV-2 Spike RBD protein (Sino Biological, 40592-V08H2-B) was mixed with Streptavidin BV421 (Biolegend, 405225) at a 4:1 molar ratio for 1 h at 4°C to obtain the antigen probe. According to the manufacturer's instruction, PBMCs were stained for 30 min at 4°C using an antigen probe (1:33.3) and the following conjugated antibodies: anti-human CD3 (300430, Biolegend, 1:50), anti-human CD19 (302212, Biolegend, 1:50), anti-human CD21 (354918, Biolegend, 1:50), anti-human CD27 (356406, Biolegend, 1:50).…”

Section: Detection Of Sars-cov-2-specific Mbcsmentioning

confidence: 99%

See 2 more Smart Citations

Dynamic immunogenicity after primary and booster inactivated SARS‐CoV‐2 vaccination in people living with HIV: A longitudinal observational study

Chen

Cao

et al. 2023

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

People living with HIV (PLWH) have poor outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); vaccination reduces the associated mortality. The humoral immune response dynamics after booster inactivated vaccinations in PLWH remain unclear. In this longitudinal observational study, 100 PLWH after primary inactivated SARS-CoV-2 vaccination were consecutively recruited and followed up. After booster vaccination (BV), neutralizing antibodies (NAbs) were detected at 1 month from all the PLWH, and the titer increased sixfold compared to that associated with the primary vaccination (PV), similar to that in healthy controls after BV. The NAbs titer declined over time after BV, but remained higher at 6 months than after PV. The NAbs response was elevated after BV with CD4 count <200 cells/μL, it was the poorest among the different CD4 cell count subgroups. Similar results were observed for anti-RBD-IgG responses. Moreover, RBD-specific MBCs were significantly elevated after BV in PLWH. No serious AEs were observed after BV in PLWH. In conclusion, booster inactivated SARS-CoV-2 vaccination is well tolerated and can elicit robust and durable humoral responses in PLWH. PLWH may benefit from a third dose of the inactivated vaccine.

show abstract

Section: Participants and Methodsmentioning

confidence: 99%

Section: Participants and Methodsmentioning

confidence: 99%

Section: Detection Of Sars-cov-2-specific Mbcsmentioning

confidence: 99%

See 1 more Smart Citation

Dynamic immunogenicity after primary and booster inactivated SARS‐CoV‐2 vaccination in people living with HIV: A longitudinal observational study

Chen

Cao

et al. 2023

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The antireceptor-binding-domain IgG (anti-RBD-IgG) and neutralizing antibodies (NAbs) in serum samples were evaluated using capture chemiluminescence immunoassays by MAGLUMI X8 (Snibe, Shenzhen, China), as previously described. 20 The sensitivity and specificity of the kits (Snibe) for anti-RBD-IgG are 100% and 99.6%, respectively, and those for NAbs are 100% and 100%, respectively. The cut-off value was 1.00 AU/mL for anti-RBD-IgG and 0.15 µg/mL for NAbs.…”

Section: Methodsmentioning

confidence: 98%

Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases

Chen,

Wang,

et al. 2023

J Clin Transl Hepatol

Self Cite

View full text Add to dashboard Cite

Background and Aims SARS-CoV-2 vaccines-associated autoimmune liver diseases have been reported in several case reports. However, the safety and immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in patients with autoimmune liver diseases (AILD) is still unknown. Methods Eighty-four patients with AILD were prospectively followed up after the second dose (primary) of inactivated SARS-CoV-2 vaccine. Some of them received the third dose (booster) of inactivated vaccine. Adverse events (AEs), autoimmune activation, and liver inflammation exacerbation after primary and booster vaccination were recorded. Meanwhile, dynamics of antireceptor-binding-domain IgG (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD-specific B cells responses were evaluated. Results The overall AEs in AILD patients after primary and booster vaccination were 26.2% and 13.3%, respectively. The decrease of C3 level and increase of immunoglobulin light chain κ and λ levels were observed in AILD patients after primary vaccination, however, liver inflammation was not exacerbated, even after booster vaccination. Both the seroprevalence and titers of anti-RBD-IgG and NAbs were decreased over time in AILD patients after primary vaccination. Notably, the antibody titers were significantly elevated after booster vaccination (10-fold in anti-RBD-IgG and 7.4-fold in NAbs, respectively), which was as high as in healthy controls. Unfortunately, the inferior antibody response was not enhanced after booster vaccination in patients with immunosuppressants. Changes of atypical memory B cells were inversely related to antibody levels, which indicate that the impaired immune memory was partially restored partly by the booster vaccination. Conclusions The well tolerability and enhanced humoral immune response of inactivated vaccine supports an additional booster vaccination in AILD patients without immunosuppressants.

show abstract

“…The anti-receptor-binding-domain IgG (anti-RBD-IgG) and neutralizing antibodies (NAbs) in serum samples were detected using capture chemiluminescence immunoassays by MAGLUMI X8 (Snibe, Shenzhen, China), as described in our previous study ( Chen et al., 2023 ). The sensitivity and specificity of anti-RBD IgG were 100% and 99.6%, respectively, and those of NAbs tests were both 100%.…”

Section: Participants and Methodsmentioning

confidence: 99%

Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection

Zhou

Chen

et al. 2023

Front. Cell. Infect. Microbiol.

Self Cite

View full text Add to dashboard Cite

BackgroundInactivated SARS-CoV-2 vaccination has recently been approved for children aged 3-17 years in China. However, data on long-term humoral responses to inactivated vaccines in children with chronic hepatitis B (CHB) are still limited.MethodsIn this prospective observational study, CHB children after primary inactivated SARS-CoV-2 vaccines were recruited consecutively and followed up for 1 year. CHB adults from another cohort study (NCT05007665) were used as a control. The receptor-binding domain IgG antibody (anti-RBD-IgG), neutralizing antibody (NAb), neutralization against Omicron (BA2.12.1, BA.4 and BA.5), and memory B -cell (MBC) responses were evaluated.ResultsOverall, 115 CHB children and 351 CHB adults were included in this analysis. The antibody titers decreased over the first ~180 days and then plateaued up to 1 year in CHB children. However, lower and faster declines in antibody responses were observed in CHB adults. Interestingly, the seroprevalence of antibodies was still high after over 8 months in CHB children (anti-RBD-IgG [90%] and NAbs [83%]). However, neutralization against Omicron subvariants was significantly reduced in CHB children (-3.68-fold to -8.60-fold). Notably, neutralization against the BA.5 subvariant was obviously diminished in CHB children compared with adults. Moreover, CHB children had similar RBD-specific MBCs but higher RBD-specific atypical MBCs compared with adults.ConclusionInactivated vaccination could elicit more robust and durable antibody responses to the wild-type SARS-CoV-2 strain in CHB children than in CHB adults but showed inferior responses to Omicron subvariants (especially to the BA.5 strain). Hence, new Omicron-related or all-in-one vaccines are needed immediately for CHB children.

show abstract

Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors

Cited by 4 publications

References 10 publications

Dynamic immunogenicity after primary and booster inactivated SARS‐CoV‐2 vaccination in people living with HIV: A longitudinal observational study

Dynamic immunogenicity after primary and booster inactivated SARS‐CoV‐2 vaccination in people living with HIV: A longitudinal observational study

Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases

Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection

Contact Info

Product

Resources

About